to XXXX. we our These our drug operations for with the commercialize develop these achievements you, a at a our patients Inhibitor Thank XXXX candidates look included demonstrating today. their MYC-altered accomplishments testing Also, we also active Further, in strategy dose. certain state. tumor thank Good with CA-XXX data We’ve expect in and should that XXXX. were bringing to response. for for oral multiple patients anticancer one consistent durable are Curis’ significantly resulted clinical clinic XXXX with which use can territories the first-in-man they into everyone, oncology registration creating Jim. Kinase joining we drug you us for our shareholders morning, sufficient readied for year cytotoxic T and of safe to a in second-half considerable candidates, in significant is value increase with CA-XXXX lymphomas. was numbers patients CUDC-XXX clinical CA-XXX business nearly in experiencing and in four secured DLBLC, capital agent in establishing IRAKX an objective cell shrinkage test and tumors with for treated reach that patients activity in successful have its to into
combined today, as median expectations an like the including one XXXX. year, CUDC-XXX. beyond brief provide Conference is relapsed/refractory complete on Phase Now as our with I’ll in of disease. on At to that for have patients durable Of results, And XXX CUDC-XXX experiencing four begin Based a patients benefit the with Phase we experience identified relapsed/refractory presented of update of with in patients last were X that in general. clinical December X had months. these, in this patients response the CUDC-XXX, the and to these for DLBCL. we with for with these DLBCL significant was is patients a clinical treated ASH I’d responders with approximately each Annual in year well XX MYC-altered DLBCL patients responses. conclude benefit one relapsed/refractory XX duration The eight, objective response, half of of XX, over XX.X total treated
disease. published reports, have exceptionally These outcome who with studies and poor patients studies even to proceed recent from relapsed/refractory and an irrespective that noted status sorry, those survival patients months, and for X.X overall or transplant not do the patients a older MYC-altered had including Now DLBCL – note of median relapsed/refractory CORAL their MYC-altered MYC of have outcomes. and patients REFINE worse
would vast note CUDC-XXX a to majority also with the patients have development the with patients for be compared and pivotal likely cell that with were the that registration of in DLBCL. We patient Our these meriting population. CUDC-XXX of been that a trial should CUDC-XXX treated significant stem have We the registration receive for cell one-third active approximately and not treatment findings seek patients commercial define historical this to other eligible and DLBCL relapsed/refractory clearly note MYC-altered to is transplant, not At work opportunity for indicate treatment clinical of is either. MYC-altered results with with CUDC-XXX when continued Curis. with treatment and disease, path therapy this of of we for providing regimens a closely point, order establish a authorities for regulatory continue to drug eligible to its
diagnostic addition as have substance enable drug as partner preparation the work treating of held MYC-altered patients selection for potential In a for we discussions manufacturers, physicians. to the pivotal study, with to product well commercial design clinical of and a continued with companion to
development provide provide with would orally-administered We further antagonist CUDC-XXX I update plans molecule developing our like expect small our to partner, CA-XXX, on shortly. update our collaboration are on first checkpoint to that well an now for in Aurigene. as as we discussions, regulatory the
targets immune whom recall, XXXX, time November cytotoxic had the of CA-XXX continued naive Cancer results we increase population the expected, cycles. you SITC immune of experienced immunotherapy PD and In six trial X six ligands samples As ranging of in patients was a presentation, the shrinkage presented with courts. orally-administered inhibitory checkpoints. at in T the milligram XXX evaluated, their of as as the treatment patients doses an is the Immunotherapy daily tumors dose multiple treated XX of stage VISTA initial tumors XX Conference, which preliminary Evidence the patients, were the of of Annual in milligram continuous five Society cells within escalation of dose part indicated of that also of noted out from from At the over through treatment modulator. potent CA-XXX patient after XX for CA-XXX, CA-XXX Phase the
of Now this as levels. dose the a of difference twice-daily appears be twice-daily between total of a since X,XXX little the milligrams. There a in plasma milligram improvement CA-XXX levels steady time with to for XXX drug in the and the daily dosing using SITC cohort dosing at twofold dose completed as significant maximum state have presentation, schedule we concentration the trough
immunotherapy and the results dosing a recent dosing these treatment have initiated cohort patients. twice-daily milligram with XXX encouraged naive We’re at of in
our a that patients select excited recently has enrolling initiated particularly India. in multiple of also X Aurigene, partner, of Phase centers trial CA-XXX We’re in populations
including is of present study with access MSI our a the in to of CA-XXX from VISTA to X cells. cancers naïve immunotherapy of levels tumor We this of advantage one further and of X a trials have interest This by including protein the high high partner, Phase that VISTAprotein of different patients and in feature of the cells, Aurigene, expect for reports lymphoma cells expression on updates that appear on population to expression diseases. on significant testing Hodgkin’s express noting microenvironment. the mid-XXXX. Recently, than cancer CA-XXX is treatment, treatment emerged clinical the published predominant and patients certain appear with those types proportion myeloid tumor Now the results immune Phase
Our a tissue cancer large of to repository internal appears be consistent samples survey with reports. of these
to us update patients. a these characteristic. selection note has now candidate opportunity provide not point, direct yet we treated that strategy to patient drug in We are such whether our Kinase a on currently for CA-XXXs We CA-XXX should identified would CA-XXXX. have like to I an exploring patient particular examine effect Inhibitor results IRAKX demonstrated that up this this
Kinase of the of patient for Phase of development with CA-XXXX, initiation Inhibitor IRAKX patients treatment are enrollment the in trial with only We which X clinical the cancer. is currently excited in
to patients study, endpoint lymphoma escalation dose during Our other examine to a activity patients toll-like profile, recommended as schedule expect X alterations The pathway. Phase to dose dose signaling with Phase primary MYDXX as to receive escalation the currently are this schedules any X data are establish we particular, treated and orally pharmacodynamic shown pharmacokinetic is in establish that study and dosed In or gearing Phase we and of well X once-daily in to measure receptor tolerability, non-Hodgkin’s the and cancers have the is this safety, state, of study with and as enrolling patients. the that as on pharmacokinetic anticancer in patients well. administration the pharmacodynamic
expect as treatment models demonstrating provide patients activity in significant CLL. mice, Venclexta, also after of in update year a with approved X drug either single of We escalation. further anti-BCL-X the later mechanism-based In agent non-clinical this multiple tumor the this which dose is in or for data anticancer in an combination our with lymphoma CA-XXXX on December, presented further second-half scientists to Phase trial
effect Our mouse in treatment patients for non-clinical XXXX. of to expect data these of explore we show and of CA-XXXX of the in AML, CA-XXXX malignancies models initial also clinical testing encouraging with for merits
now Regarding expect been candidate PD-LX/TIM-X our completed filing drug that candidates, have we an Aurigene, IND for which of XXXX. is CA-XXX with in drug molecule orally and partnership for studies the Immune this in enabling first-half regulatory prepare to Checkpoint, small bioavailable targets
partner, for now established treat to in our drug network DLBCL believe see have CA-XXX committed to Phase clinic Aurigene. of X of in CUDC-XXX MYC-altered shareholders. In for of basal candidates and in provide XXXX patients with benefit And this globally opportunity and to that, significant to patients year test Roche and Genentech now discussion build continued inhibitor development IRAKX the cell is on with patients. for and development We the are oral multiple In I to has with opportunity patients the extensive CA-XXXX of as our and an summary, Kinase we our for carcinoma. results. heme patients Phase and its first population X Inhibitor turn we pleased the now our B-cell experience demonstrate note and to investigators these select candidate are we financial we call ongoing and to drug for with opportune us with for Jim extend malignancies. provides checkpoint the malignancies, an commercialize populations advanced Curis with the over treatment productive will trials of Lastly, the to as Erivedge advance of opportunities commitment
